Trial Profile

A Multicenter, Randomized, Double-masked, Vehicle-controlled Study to Assess the Safety and Efficacy of SYD-101 Ophthalmic Solution for the Treatment of Myopia in Children

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 01 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atropine (Primary)
Indications Myopia
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms STAR
Sponsors Sydnexis

Most Recent Events

04 Nov 2025 According to a Sydnexis media release, findings from this study presented in a poster session at Academy of Managed Care Pharmacy (AMCP) Nexus 2025 in National Harbor, MD.
04 Nov 2025 topline results from the Phase 3 STAR trial of SYD-101 published in the Sydnexis Media Release
04 Nov 2025 Primary endpoint has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com